Data as of 10:58am ET
| +0.069 / +2.51%|
The 3 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +112.77% increase from the last price of 2.82.
The current consensus among 3 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.